Tag Archives: PT

FDA misconduct not deemed newsworthy

By Kelly Roman, Vice President of Fisher Wallace Labs On February 10, 2012, the FDA convened an advisory panel hearing on whether to reclassify cranial electrotherapy stimulation (CES) devices. Despite being a low-risk device, CES has lingered in Class 3…

FacebookTwitterGoogle+Share

Marketo